5 clinical trials demonstrated significant weight reduction

The chart comparing the effectiveness of Tirzepatide (in various doses) to Placebo, Insulin Semaglutide, Insulin Degludec, Insulin Glargine and Basal insulin+ Metformin in lowering weight in adults with type 2 diabetes.

Key findings: Tirzepatide at all doses (5 mg, 10 mg and 15 mg) demonstrated significantly greater weight reduction compared to Placebo, Insulin Semaglutide, Insulin Degludec, Insulin Glargine and Basal insulin+ Metformin.

This indicates that Tirzepatide might be a more effective treatment option for achieving better weight reduction in patients with type 2 diabetes.